Intensity Therapeutics, Inc
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing intratumoral cancer therapies designed to be injected directly into tumors. Its lead candidate, INT230-6, combines two cytotoxic agents with a proprietary amphiphilic molecule to help the drugs spread within the tumor and enter cancer cells.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaINT230-6 is the company's main intratumoral oncology therapy under clinical development.
INVINCIBLE-3 and INVINCIBLE-4 are the core studies advancing the lead candidate.
GMP batch production, labeling, stability testing, and related supply work for trials.
Asiakkaat
The company does not yet sell products and has not generated revenue from product sales or licensing. Its near-term 'customers' are clinical trial sites, investigators, regulators, and eventually oncology patients and treating physicians if INT230-6 is approved. Any future commercial buyers would likely include hospitals, cancer centers, and payers supporting oncology treatment access.
They administer the studies, collect data, and generate the evidence needed for regulatory approval.
Patients with solid tumors are the intended end users of the intratumoral therapy in trials and, later, commercialization.
FDA and other agencies determine whether the product can advance from trials to marketing approval.
These would be the main institutional buyers if the therapy reaches market and is adopted in oncology practice.
Strategia
Intensity Therapeutics is focused on funding and advancing its INVINCIBLE-3 and INVINCIBLE-4 studies, while building the manufacturing, regulatory, and organizational infrastructure needed for approval. The company also needs to preserve intellectual property and prepare a future commercial platform, but its strategy remains dependent on external financing until any product reaches market.
Clinical proof-of-concept is the main value driver for a pre-revenue biotech company.
GMP batches and stability testing are required to support ongoing trials and future approval.
Approval and eventual launch require regulatory filings, sales capability, and medical affairs readiness.
Maantiede
The company is based in the United States and its operations are centered on U.S.-based clinical development, manufacturing, and capital markets access. The filings do not disclose meaningful country revenue because the company has not generated product revenue. Geography matters mainly through U.S. regulatory oversight, domestic trial execution, and exposure to U.S. tariff and import/export policy for clinical supply chains.
Riskit
The company is highly dependent on clinical success, regulatory approval, and the ability to raise capital before any product revenue exists. It also faces typical biotech risks such as trial delays, manufacturing complexity, IP protection, and commercialization uncertainty, plus the specific risk of Nasdaq listing compliance and policy changes affecting imports and tariffs.
- Financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company expects to fund operations through equity, debt, or collaborations until commercialization.
Kohdistuu: Operating runway and trial funding
- Clinical development failureVaikutus: Kriittinen
INT230-6 must show safety and efficacy in trials before it can generate revenue.
Kohdistuu: INVINCIBLE-3 and INVINCIBLE-4
- Nasdaq delisting riskVaikutus: KorkeaTodennäköisyys: Korkea
Failure to regain compliance with listing standards could reduce liquidity and capital access.
Kohdistuu: Common stock trading and future fundraising
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Matala
Even successful trials may not translate into marketing approval or commercial launch.
Kohdistuu: FDA and other health authorities
- Trade policy and tariff riskVaikutus: Keskitaso
Clinical and manufacturing inputs may be affected by import/export rules and tariffs.
Kohdistuu: Supply chain and third-party manufacturing
Kirjanpito
Harkinnanvaraiset erätClinical, manufacturing, and personnel costs are expensed immediately and dominate the income statement.
Vaikutus: Directly affects operating loss and cash burn
Employee options and consultant warrants create non-cash expense and dilution.
Vaikutus: Affects reported operating expense and share count
Recent offerings and warrants may require valuation judgments and influence dilution.
Vaikutus: Affects equity balances and per-share metrics
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Inhibitor Therapeutics, Inc.
INTI · Pharmaceutical Preparations
Indaptus Therapeutics, Inc.
INDP · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Päivitetty: 24.9.2026